Clinical Trials Logo

Advanced/Metastatic Solid Tumors clinical trials

View clinical trials related to Advanced/Metastatic Solid Tumors.

Filter by:

NCT ID: NCT03833427 Completed - Clinical trials for Advanced/Metastatic Solid Tumors

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

Start date: March 18, 2019
Phase: Phase 1
Study type: Interventional

This study will examine the safety, pharmacokinetics, and efficacy of escalating doses of selumetinib (MK-5618) in combination with intravenous (IV) pembrolizumab (MK-3475) for participants with advanced / metastatic solid tumors.

NCT ID: NCT03526835 Recruiting - Colorectal Cancer Clinical Trials

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Start date: May 2, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the RP2D of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer. The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158.

NCT ID: NCT02665416 Completed - Clinical trials for Advanced/Metastatic Solid Tumors

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Start date: January 25, 2016
Phase: Phase 1
Study type: Interventional

This open-label, two-part study is designed to assess the safety, PK, PD, and therapeutic activity of Selicrelumab in combination with vanucizumab or bevacizumab in participants with metastatic solid tumors not amenable to standard treatment. Part I (dose escalation) is designed to establish the maximum tolerated dose (MTD) of Selicrelumab in this combination. Part II (expansion) is intended to characterize the safety and tolerability of Selicrelumab in combination with bevacizumab among indication-specific cohorts and to confirm the recommended dose.

NCT ID: NCT02444793 Terminated - Clinical trials for Advanced/Metastatic Solid Tumors

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Start date: May 2015
Phase: Phase 1
Study type: Interventional

This study is a Phase 1b, open label, multi center, multi-dose trial designed to estimate the maximum tolerated dose (MTD) and select the recommended dose for phase 2 (RP2D) investigations of PF- 05082566 in combination with KW-0761 (mogamulizumab) in patients with advanced solid tumors. Once the MTD of PF-05082566 administered in combination with KW-0761 is estimated (dose finding), one or more expansion cohorts of patients with selected advanced solid tumors (dose-expansion ) will be enrolled to further characterize the combination in term of safety profile, anti tumor activity, pharmacokinetics, pharmacodynamics and biomarkers modulation.

NCT ID: NCT01092052 Terminated - Clinical trials for Advanced/Metastatic Solid Tumors

Study of NMS-1116354 in Advanced/Metastatic Solid Tumors

Start date: January 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced/metastatic solid tumors.

NCT ID: NCT00996255 Terminated - Clinical trials for Advanced/Metastatic Solid Tumors

Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors

Start date: November 2006
Phase: Phase 1
Study type: Interventional

The purpose of this open-label, multi center, phase I study, was to determine the safety profile of PHA-793887 administered by intravenous infusion to patients with advanced/metastatic solid tumors. This was a dose-finding study to determine the maximum tolerated dose and the dose of PHA-793887 that can be safely used in phase II investigations.